Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 13,550 |
|
|||||
| News | - | ||||||
| Day High | 5.525 | Low High |
|||||
| Day Low | 4.92 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CalciMedica Inc | CALC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.54 | -9.84% | 4.95 | 12:43:12 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.98 | 4.92 | 5.525 | 5.49 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 99 | 13,550 | $ 5.11 | $ 69,230 | - | 1.75 - 8.59 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:11:49 | 15 | $ 5.25 | USD |
CalciMedica Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 28.65M | 5.68M | - | 0 | -34.36M | -6.04 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CalciMedica News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CALC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.19 | 5.80 | 4.01 | 5.22 | 21,112 | 0.76 | 18.14% |
| 1 Month | 3.91 | 5.80 | 3.88 | 4.55 | 19,894 | 1.04 | 26.60% |
| 3 Months | 7.11 | 7.76 | 3.3101 | 4.48 | 21,336 | -2.16 | -30.38% |
| 6 Months | 1.78 | 8.38 | 1.75 | 4.27 | 19,139 | 3.17 | 178.09% |
| 1 Year | 4.70 | 8.59 | 1.75 | 3.92 | 18,682 | 0.25 | 5.32% |
| 3 Years | 5.27 | 8.59 | 1.75 | 4.06 | 19,557 | -0.32 | -6.07% |
| 5 Years | 5.27 | 8.59 | 1.75 | 4.06 | 19,557 | -0.32 | -6.07% |
CalciMedica Description
| CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. |
